SCYNEXIS, Inc.
P.O. Box 12878
Research Triangle Park
North Carolina
27709
United States
Tel: 919-544-8600
Fax: 919-544-8697
Website: http://www.scynexis.com/
Email: terry.marquardt@scynexis.com
330 articles about SCYNEXIS, Inc.
-
SCYNEXIS, Inc. Presents New Data Further Supporting SCY-078 As A Potential Treatment For Aspergillus And Candida Infections At IDWeek 2017
10/5/2017
-
SCYNEXIS, Inc. Presents New Data Supporting Oral SCY-078 For The Clinical Treatment Of Vulvovaginal Candidiasis Infections At The 2017 IDSOG Annual Meeting
8/14/2017
-
SCYNEXIS, Inc. Reports Second Quarter 2017 Financial Results And Provides Company Update
8/9/2017
-
SCYNEXIS, Inc. Announces Initiation of Dosing in Phase II Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
8/4/2017
-
New Study Further Demonstrates In Vitro Activity Of SCYNEXIS, Inc.’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
6/15/2017
-
SCYNEXIS, Inc. Release: Eight Presentations At ASM Microbe 2017 Further Highlight The Strong Antifungal Effect And Promising Safety Profile Of Lead Anti-Infective Candidate SCY-078
6/5/2017
-
Eight SCY-078 Data Presentations At ASM Microbe 2017 Confirm Potential Of SCYNEXIS, Inc.’ Lead Agent To Combat Serious And Life-Threatening Fungal Infections
5/24/2017
-
Potent In Vitro Activity Of SCYNEXIS, Inc.’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida Auris Further Confirmed In An In Vitro Study Conducted By The CDC
5/11/2017
-
SCYNEXIS, Inc. Reports First Quarter 2017 Financial Results And Provides Update On IV Formulation Development Status
5/9/2017
-
Eight Data Presentations At ECCMID Showcase The Broad Applicability Of SCYNEXIS, Inc.’ Lead Anti-Infective Candidate SCY-078
4/25/2017
-
SCYNEXIS, Inc. To Host A Conference Call To Discuss Lead Anti-Infective Candidate SCY-078 Data Presented At 27th ECCMID
4/21/2017
-
SCYNEXIS, Inc. Delays Initiation Of New Clinical Studies Using The IV Formulation Of SCY-078 At FDA’s Request
3/3/2017
-
SCYNEXIS, Inc. Release: Company Announces Appointment Of Industry Veteran Marion Mccourt To Its Board Of Directors
1/26/2017
-
SCYNEXIS, Inc. Achieves New Development Milestones Reinforcing The Versatility Of SCY-078 In Treating Serious Fungal Infections
12/13/2016
-
SCYNEXIS, Inc. Completes Two Additional Clinical Studies Further Supporting The Favorable Safety Profile Of SCY-078
10/25/2016
-
Why SCYNEXIS, Inc. Is Making A Run
10/7/2016
-
SCYNEXIS, Inc. Announces Complete Results From Two Phase II Studies Of Oral SCY-078 In Patients With Candida Spp. Infections And Closing Of A $15 Million Term Loan
10/6/2016
-
SCYNEXIS, Inc. To Present At The Ladenburg Thalmann Healthcare Conference
9/20/2016
-
SCYNEXIS, Inc. To Present At Upcoming Investor Conferences
8/31/2016
-
SCYNEXIS, Inc. Receives Orphan Drug Designation For SCY-078 For The Treatment Of Invasive Aspergillus Infections
8/25/2016